LHRH analogues and breast cancer
1991
LHRH Analogues and Breast Cancer
Editorial
Author Information
Author(s): E. Korkut, A.M. Comaru-Schally, A.V. Schally, P.N. Plowman
Primary Institution: Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center
Hypothesis
The use of LHRH analogues in breast cancer treatment may not be as effective as previously thought.
Conclusion
Newer LHRH antagonists may offer advantages in breast cancer treatment over traditional methods.
Supporting Evidence
- New LHRH antagonists can provide immediate medical castration without initial stimulation.
- Studies suggest LHRH antagonists may inhibit cell growth in certain breast cancer cell lines.
- Tamoxifen treatment has been associated with relapses in patients.
Takeaway
Doctors are looking at new medicines that can help treat breast cancer better and faster than older treatments.
Potential Biases
The editorial suggests that the viewpoints expressed in the original editorial may not be definitive or correct.
Limitations
The editorial critiques the low statistical power of the cited trials comparing tamoxifen and oophorectomy.
Want to read the original?
Access the complete publication on the publisher's website